Oppenheimer Cuts Perspective Therapeutics (NYSE:CATX) Price Target to $16.00

Perspective Therapeutics (NYSE:CATX) had its target price trimmed by Oppenheimer from $22.00 to $16.00 in a research note published on Friday,Benzinga reports. The firm currently has an outperform rating on the stock.

CATX has been the subject of a number of other reports. Bank of America assumed coverage on Perspective Therapeutics in a research note on Thursday, July 25th. They issued a “buy” rating and a $24.00 target price for the company. Cantor Fitzgerald restated an “overweight” rating on shares of Perspective Therapeutics in a research note on Monday, September 9th. Wedbush reiterated an “outperform” rating and issued a $11.00 target price (down from $20.00) on shares of Perspective Therapeutics in a research note on Thursday. UBS Group began coverage on shares of Perspective Therapeutics in a research report on Thursday, October 24th. They set a “buy” rating and a $20.00 price target for the company. Finally, Royal Bank of Canada cut their price objective on shares of Perspective Therapeutics from $29.00 to $27.00 and set an “outperform” rating on the stock in a research report on Friday, August 16th. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $19.43.

Perspective Therapeutics Stock Up 15.7 %

Shares of CATX opened at $3.47 on Friday. Perspective Therapeutics has a 52 week low of $2.28 and a 52 week high of $19.05. The business has a 50 day moving average price of $11.52.

Perspective Therapeutics (NYSE:CATX) last released its earnings results on Tuesday, November 12th. The company reported ($0.21) earnings per share for the quarter, meeting the consensus estimate of ($0.21). Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%. The firm had revenue of $0.37 million during the quarter. Equities analysts expect that Perspective Therapeutics will post -0.86 earnings per share for the current year.

Institutional Trading of Perspective Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its holdings in shares of Perspective Therapeutics by 34.6% in the first quarter. Vanguard Group Inc. now owns 17,780,106 shares of the company’s stock valued at $21,158,000 after buying an additional 4,566,356 shares during the period. Janus Henderson Group PLC acquired a new stake in Perspective Therapeutics in the 1st quarter valued at about $15,511,000. Virtu Financial LLC bought a new position in shares of Perspective Therapeutics during the 1st quarter valued at about $138,000. Bank of New York Mellon Corp grew its stake in shares of Perspective Therapeutics by 214.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 137,268 shares of the company’s stock worth $1,369,000 after purchasing an additional 93,548 shares during the last quarter. Finally, Rhumbline Advisers bought a new stake in shares of Perspective Therapeutics in the 2nd quarter worth approximately $630,000. 54.66% of the stock is currently owned by institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.